drugset / Trial / NCT00091481

Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis

NCT00091481

Phase 4 Completed 201 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose based on body weight (0.04 mcg/kg).

Timeline

Start
2003-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Paricalcitol Other / unclassified 0.04 ug/kg